Strategy for treating selective serotonin reuptake inhibitor-resistant social anxiety disorder in the clinical setting: A randomised controlled trial protocol of cognitive behavioural therapy in combination with conventional treatment

BMJ Open

Volumn 3, Issue 2, 2013, Pages

  Yoshinaga, Naoki ^a,b   Niitsu, Tomihisa ^b   Hanaoka, Hideki ^c   Sato, Yasunori ^c   Ohshima, Fumiyo ^a,b   Matsuki, Satoshi ^a,b   Kobori, Osamu ^a,b   Nakazato, Michiko ^b   Nakagawa, Akiko ^b   Iyo, Masaomi ^a   Shimizu, Eiji ^a,b  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; COGNITIVE THERAPY; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; FUNCTIONAL DISEASE; HUMAN; LIEBOWITZ SOCIAL ANXIETY SCALE; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SOCIAL PHOBIA;

EID: 84875031689     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-002242     Document Type: Article

References (69)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn. DSM-IV-TR. Washington DC: American Psychiatric Pub, 2000.
2. Stein DJ, Ruscio AM, Lee S, et al. Subtyping social anxiety disorder in developed and developing countries. Depress Anxiety 2010;27:390-403.
3. Stein MB, Roy-Byrne PP, Craske MG, et al. Functional impact and health utility of anxiety disorders in primary care outpatients. Med Care 2005;43:1164-70. (Pubitemid 43012172)
4. Wang PS, Lane M, Olfson M, et al. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:629-40. (Pubitemid 40973438)
5. Sareen J, Jacobi F, Cox BJ, et al. Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions. Arch Intern Med 2006;166:2109-16. (Pubitemid 44631399)
6. Fedoroff IC, Taylor S. Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol 2001;21:311-24. (Pubitemid 32452937)
7. Stein DJ, Ipser JC, Balkom AJ. Pharmacotherapy for social phobia. Cochrane Database Syst Rev 2004 Oct 18;(4):CD001206.
8. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008;9:248-312.
9. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol (Oxford) 2005;19:567-96. (Pubitemid 41578819)
10. Swinson RP, Antony MM, Bleau PB, et al. Clinical practice guidelines: management of anxiety disorders. Can J Psychiatry 2006;51:9S-91S.
11. Stein DJ, Baldwin DS, Bandelow B, et al. A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder. Curr Psychiatry Rep 2010;12:471-7.
12. Mörtberg E, Clark DM, Sundin O, et al. Intensive group cognitive treatment and individual cognitive therapy vs. treatment as usual in social phobia: a randomized controlled trial. Acta Psychiatr Scand 2007;115:142-54. (Pubitemid 46114875)
13. Stangier U, Heidenreich T, Peitz M, et al. Cognitive therapy for social phobia: individual versus group treatment. Behav Res Ther 2003;41:991-1007. (Pubitemid 36952355)
14. Hedman E, Andersson G, Ljótsson B, et al. Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: a randomized controlled non-inferiority trial. PLoS ONE 2011;6:e18001.
15. Blomhoff S, Haug TT, Hellström K, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001;179:23-30.
16. Davidson JRT, Foa EB, Huppert JD, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004;61:1005-13. (Pubitemid 39336534)
17. Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 1991;48:938-45.
18. Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998;55:1133-41. (Pubitemid 28558287)
19. Hofmann SG, Barlow DH, Papp LA, et al. Pretreatment attrition in a comparative treatment outcome study on panic disorder. Am J Psychiatry 1998;155:43-7. (Pubitemid 28037547)
20. Hedman E, Ljótsson B, Lindefors N. Cognitive behavior therapy via the Internet: a systematic review of applications, clinical efficacy and cost-effectiveness. Expert Rev Pharmacoecon Outcomes Res 2012;12:745-64.
21. Lepola U, Bergtholdt B, St Lambert J, et al. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 2004;65:222-9.
22. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005;62:190-8. (Pubitemid 40189136)
23. Dwight-Johnson M, Sherbourne CD, Liao D, et al. Treatment preferences among depressed primary care patients. J Gen Intern Med 2000;15:527-34.
24. Insel TR. Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Arch Gen Psychiatry 2009;66:128-33.
25. Department of Health. No health without mental health: a cross-government mental health outcomes strategy for people of all ages, London, 2011.
26. Department of Health. Talking therapies: a four year plan of action, London, 2011.
27. Pirkis J, Livingston J, Herrman H, et al. Improving collaboration between private psychiatrists, the public mental health sector and general practitioners: evaluation of the Partnership Project. Aust N Z J Psychiatry 2004;38:125-34. (Pubitemid 38488922)
28. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992;49:290-300.
29. Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993;13:423-8. (Pubitemid 24026104)
30. Blanco C, Bragdon LB, Schneier FR, et al. The evidence-based pharmacotherapy of social anxiety disorder. Int J Neuropsychopharmacol 2003;6:427-42. (Pubitemid 38146264)
31. Ipser JC, Carey P, Dhansay Y, et al. Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders. Cochrane Database Syst Rev 2006 Oct 18;(4);CD005473.
32. Liebowitz MR, Mangano RM, Bradwejn J, et al. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 2005;66:238-47. (Pubitemid 40314332)
33. Stein MB, Pollack MH, Bystritsky A, et al. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 2005;177:280-8. (Pubitemid 40137288)
34. van der Linden GJ, Stein DJ, van Balkom AJ. The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2000;15(Suppl 2):S15-23.
35. Lader M, Stender K, Bürger V, et al. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004;19:241-8. (Pubitemid 39014144)
36. Stein DJ, Stein MB, Pitts CD, et al. Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry 2002;63:152-5. (Pubitemid 34173853)
37. Stein MB, Stein DJ. Social anxiety disorder. Lancet 2008;371:1115-25. (Pubitemid 351418007)
38. Fava GA, Tomba E. Increasing psychological well-being and resilience by psychotherapeutic methods. J Pers 2009;77:1903-34.
39. Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 1996;39:115-21. (Pubitemid 26232803)
40. Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 2004;65:244-8.
41. Simon NM, Hoge EA, Fischmann D, et al. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry 2006;67:381-5.
42. Worthington JJ 3rd, Kinrys G, Wygant LE, et al. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005;20:9-11. (Pubitemid 40105542)
43. Pallanti S, Quercioli L. Resistant social anxiety disorder response to Escitalopram. Clin Pract Epidemiol Ment Health 2006;2:35.
44. Kelsey JE. Venlafaxine in social phobia. Psychopharmacol Bull 1995;31:767-71. (Pubitemid 26091745)
45. Altamura AC, Pioli R, Vitto M, et al. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol 1999;14:239-45. (Pubitemid 29358991)
46. Blanco C, Heimberg RG, Schneier FR, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 2010;67:286-95.
47. Rodrigues H, Figueira I, Gonçalves R, et al. CBT for pharmacotherapy non-remitters - a systematic review of a next-step strategy. J Affect Disord 2011;129:219-28.
48. Hofmann SG, Smits JAJ. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry 2008;69:621-32. (Pubitemid 351792338)
49. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987;22:141-73.
50. Simon NM, Otto MW, Wisniewski SR, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2004;161:2222-9. (Pubitemid 39587287)
51. Rush AJ, Zimmerman M, Wisniewski SR, et al. Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. J Affect Disord 2005;87:43-55. (Pubitemid 40828202)
52. Beesdo K, Bittner A, Pine DS, et al. Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. Arch Gen Psychiatry 2007;64:903-12. (Pubitemid 47230614)
53. Guy W, National Institute of Mental Health (U S). Psychopharmacology research branch. Division of extramural research programs. ECDEU assessment manual for psychopharmacology. Rockville, MD. : U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs 1976.
54. First MB, Gibbon M. User's guide for the structured clinical interview for DSM-IV Axis I disorders SCID-I: clinician version. Washington DC: American Psychiatric Pub, 1997.
55. First MB, Gibbon M. User's guide for the structured clinical interview for Dsm-IV Axis II personality disorders: Scid-II. Washington DC: American Psychiatric Pub, 1997.
56. Heimberg RG. Social phobia: diagnosis, assessment, and treatment. New York: Guilford Press, 1995.
57. Stangier U, Schramm E, Heidenreich T, et al. Cognitive therapy vs interpersonal psychotherapy in social anxiety disorder: a randomized controlled trial. Arch Gen Psychiatry 2011;68:692-700.
58. Clark DM, Ehlers A, Hackmann A, et al. Cognitive therapy versus exposure and applied relaxation in social phobia: a randomized controlled trial. J Consult Clin Psychol 2006;74:568-78. (Pubitemid 44128236)
59. Clark DM, Ehlers A, McManus F, et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 2003;71:1058-67. (Pubitemid 37448896)
60. Blackburn I-M, James IA, Milne DL, et al. The revised cognitive therapy scale (CTS-R): psychometric properties. Behav Cogn Psychother 2001;29:431-46. (Pubitemid 33622377)
61. Heimberg RG, Horner KJ, Juster HR, et al. Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med 1999;29:199-212. (Pubitemid 29034537)
62. Turner SM, Stanley MA, Beidel DC, et al. The social phobia and anxiety inventory: construct validity. J Psychopathol Behav Assess 1989;11:221-34. (Pubitemid 20052194)
63. Beck AT, Steer RA, Brown GK. BDI-II: Beck depression inventory manual. 2nd edn. San Antonio: Psychological Corporation, 1997.
64. Leon AC, Olfson M, Portera L, et al. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 1997;27:93-105. (Pubitemid 27407503)
65. Skevington SM, Lotfy M, O'Connell KA. The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res 2004;13:299-310. (Pubitemid 38392258)
66. EuroQol group. A new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208.
67. Zaider TI, Heimberg RG, Fresco DM, et al. Evaluation of the clinical global impression scale among individuals with social anxiety disorder. Psychol Med 2003;33:611-22. (Pubitemid 36626043)
68. Brown S, Thorpe H, Hawkins K, et al. Minimization - reducing predictability for multi-centre trials whilst retaining balance within centre. Stat Med 2005;24:3715-27. (Pubitemid 43115727)
69. Bandelow B, Baldwin DS, Dolberg OT, et al. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry 2006;67:1428-34. (Pubitemid 44583391)